Clinical Trial Update: Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of twice-daily oral iptacopan (LNP023) in adults with paroxysmal nocturnal hemoglobinuria who are naive to comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (LNP023) (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: COMPLETED | Results posted: 2023-11-15